Meike HUTT
9Patents
2h-index
22Co-inventors
43Inventor score
Filing activity: Mar 18, 2016 → Dec 13, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10428120B2 | Serum half-life extension using IgBD | Chemistry; Metallurgy | 16 | Active |
| US10889645B2 | Engineered T cell receptors and immune therapy using the same | Chemistry; Metallurgy | 2 | Active |
| US10618956B2 | Engineered T cell receptors and immune therapy using the same | Chemistry; Metallurgy | 1 | Active |
| US11840577B2 | Antigen binding proteins specifically binding MAGE-A | Chemistry; Metallurgy | 1 | Active |
| US11008402B2 | Antigen binding protein against HER3 | Chemistry; Metallurgy | 0 | Active |
| US10428149B2 | Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof | Chemistry; Metallurgy | 0 | Active |
| US12269881B2 | Antigen binding proteins specifically binding MAGE-A | Chemistry; Metallurgy | 0 | Active |
| US11859009B2 | Antigen binding proteins specifically binding PRAME | Chemistry; Metallurgy | 0 | Active |
| US11932689B2 | Engineered T cell receptors and immune therapy using the same | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.